We are live on ! Find out more

Palisade Bio

PALI

Market cap $197M

1.13 USD

-0.03

2.59%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

1.13

0.00

0%

1 day

-2.59%

5 days

-5.83%

1 month

-24.16%

3 months

-45.93%

6 months

-43.5%

Year to date

-54.8%

1 year

-31.93%

5 years

-99.95%

10 years

-100%

About: Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Employees: 14

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 10%

Neutral 90%

Negative 0%

Palisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 Inhibitor

I initiate Palisade Bio with a "Buy" rating, driven by its differentiated oral PDE4 inhibitor prodrug PALI-2108 targeting inflammatory bowel diseases. PALI's phase 2b ASCENTRA-UC trial for ulcerative colitis has begun dosing, with 12-week topline results expected in Q4 2027, offering a catalyst. Expansion opportunities include a phase 2a trial in Crohn's disease [Q1 2027 start, Q1 2028 data] and potential in fibrostenotic Crohn's, leveraging proven PDE4 biology.

Palisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 Inhibitor

Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis

PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability

Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026

Five-patient Phase 1b Crohn's disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026

Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn's disease

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026

Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's

Palisade Bio NASDAQ: PALI said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program.

Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027 Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that Health Canada has cleared the Company's Clinical Trial Application (CTA) for ASCENTRA-UC, its global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis (UC).

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD

ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn's disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 Phase 2 program builds on clinical experience in fibrostenotic Crohn's disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic activity Denver, CO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for PALI-2108, enabling initiation of the Phase 2 ASCENTRA-CD clinical trial in patients with moderate to severe Crohn's disease (CD).

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD

Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that JD Finley, Chief Executive Officer, and Mitchell Jones, M.D.

Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Palisade Bio to Participate in Upcoming Investor Conferences

Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026.

Palisade Bio to Participate in Upcoming Investor Conferences

See News Rankings

Price charts implemented using Lightweight Charts™